We hypothesized that tumor necrosis factor receptor 1 (TNFR1) levels are associated with long-term trajectories of functional status independently of vascular risk factors and the occurrence of stroke and myocardial infarction (MI) during follow-up. In the Northern Manhattan Study, stroke-free persons aged ≥40 years in northern Manhattan (New York, New York) had annual assessments with the Barthel index (BI) for a median of 13 years . Assessment of baseline demographic factors, risk factors, and laboratory studies included measurement of TNFR1 (n = 1,863). Generalized estimating equations models were used to estimate standardized associations between TNFR1 and 1) baseline functional status and 2) change in function over time, adjusting for demographic factors, vascular risk factors, social variables, cognition, and depression, as well as stroke and MI occurrence during follow-up. The mean age of participants was 70 (standard deviation (SD), 10) years; 66% were women, and 55% were Hispanic. The mean TNFR1 level was 2.57 mg/L. TNFR1 was associated with baseline BI (−0.93 BI points per SD increment in TNFR1; 95% confidence interval: −1.59, −0.26) and change over time (−0.36 BI points per year per SD increment in TNFR1; 95% confidence interval: −0.69, −0.03). In this large population-based study, higher TNFR1 levels were associated with greater baseline disability and disability over time, even with adjustment for baseline covariates and stroke and MI occurrence during follow-up. biomarkers; disability; functional status; inflammation; tumor necrosis factor receptor 1 Abbreviations: BI, Barthel index; CI, confidence interval; GEE, generalized estimating equations; MI, myocardial infarction; NOMAS, Northern Manhattan Study; QIC, quasi-likelihood under the independence model criterion; TNF, tumor necrosis factor; TNFR1, tumor necrosis factor receptor 1.
Inflammatory processes have been shown to play a significant role in vascular disease and progressive neurodegenerative disease, but more research is needed to clarify the associations between inflammatory states and long-term functional trajectories. Tumor necrosis factor (TNF) α is a cytokine that is involved in various physiological and pathological processes, including inflammation, infection, thrombogenesis, cancer, and autoimmunity (1) . Endogenous TNF receptor 1 (TNFR1) is one of the 2 major receptors to which TNF binds, and binding enhances inflammation, engages pathways that clear pathogens, and causes cytotoxic effects (2) . In distinction, TNF receptor 2 is more involved in cell proliferation effects (2) . TNFR1 can be cleaved from the membrane of inflammatory cells and circulate in the blood, where it can be measured as a marker of inflammatory activity. Whereas TNF is a less reliable marker because of its relative instability, TNFR1 is more stable and amenable to reliable measurement in large populationbased studies. Elevated serum TNFR1 levels have been associated with autoimmune diseases and vascular conditions, including stroke (3, 4) . TNFR1 is expressed in many tissue types and is elevated in response to TNF-induced inflammation. It has been shown to be associated with mortality in disparate diseases (5) (6) (7) . Prior studies (1, 8) have demonstrated a role for TNF pathways in acute and long-term responses to cerebrovascular disease, frailty, and disability (9) . TNF pathways have acute and chronic inflammatory effects depending on the specific stimulating factor, duration of exposure, and milieu of activation (10) . TNF activation may have chronic, ongoing detrimental effects on peripheral or central nervous system structure and function (11) .
We hypothesized that elevated levels of serum TNFR1 are independently associated with worse functional status in persons free of stroke at baseline. Functional trajectories refer to functional status over the course of time, estimated either in an individual or, as in this analysis, within a population. We estimated 2 components of functional trajectories in this cohort: baseline functional status ( Figure 1A ) and change over time ( Figure 1B ). Since a change in the baseline or intercept of the estimated curve shifts the entire curve, such a change can be considered a change in overall or mean function. However, we will refer to this kind of change as change in baseline function. A factor may alternatively influence change in functional status over time ( Figure 1B ), which can be conceived of as altering the slope of the estimated trajectory.
METHODS
The Northern Manhattan Study (NOMAS), a populationbased prospective cohort study of persons who were free of stroke at baseline, was originally designed to evaluate the determinants of stroke and incident vascular disease in a racially/ethnically diverse community. A total of 3,298 participants were recruited by random digit dialing of published and unpublished telephone numbers between 1993 and 2001. Participants were enrolled if they: 1) were at least 40 years of age; 2) lived in a predefined geographical area of northern Manhattan (New York, New York) for at least 3 months in a household with a telephone; and 3) did not have a history of stroke. The study was approved by the institutional review boards of Columbia University and the University of Miami, and informed consent was obtained from all participants. Further characteristics of the cohort have been previously described (12) (13) (14) . We restricted the sample for this analysis to the 1,863 subjects with serum TNFR1 measurements.
Baseline evaluation
Bilingual research assistants interviewed participants and collected data using standardized questions regarding the following conditions, as previously described: hypertension, diabetes, hypercholesterolemia, cigarette smoking, alcohol use, and cardiac conditions (15) . All participants underwent a thorough baseline examination including comprehensive medical history, physical examination, review of medical records, functional status as assessed by the Barthel index (BI), quality of life as assessed by the Spitzer Quality of Life Index, and fasting blood samples.
Follow-up
All participants were followed annually via telephone screening for detection of change in vital status, new neurological or cardiac symptoms or events, interval hospitalizations, cognitive function, and functional status as assessed via the BI. Only 2 subjects were lost to follow-up after their baseline examination, and the average annual contact rate was 99%.
A positive screen for any potential cardiac or neurological event was followed by an in-person assessment to determine whether a vascular outcome occurred. In addition, all admissions and discharges were screened for hospitalizations and outcomes that may not have been captured by telephone interview. Nearly 70% of vascular events led to hospitalization at Columbia University Medical Center. Hospital records were reviewed to classify outcomes as previously reported (14) . The definition of stroke included ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. At least 2 stroke neurologists verified and classified all stroke cases. Myocardial infarction (MI) was defined by criteria adapted from the Cardiac Arrhythmia Suppression Trial (16) and the Lipid Research Clinics Coronary Primary Prevention Trial (17) , requiring at least 2 of the following 3 criteria: 1) ischemic cardiac pain determined to be typical angina; 2) cardiac marker abnormalities, defined as abnormal CK-MB fraction (the bound combination of phosphocreatine kinase isoenzymes M (muscle) and B (brain)) or troponin I values; and 
Study outcome
The BI (18, 19) measures an individual's performance in 10 Activities of Daily Living, and the score ranges from 0 to 100 in 5-point increments, with 100 indicating normal physical functioning. Previous research has demonstrated the reliability of telephone assessments of function using the BI (20) . Although the BI is an ordinal scale, researchers have recently advocated analyzing the scores as a continuous variable due to increased power to detect associations, ability to describe the course of change over time in linear form, and avoidance of potential misclassification due to crude categorization (21-23).
Explanatory variable: TNFR1
Blood samples were collected from 1,863 participants at baseline for TNFR1 analysis, and TNFR1 levels were determined using an enzyme-linked immunosorbent assay (Biosource International, Camarillo, California) in the Center for Advanced Laboratory Medicine at Columbia University Medical Center by technicians blinded to clinical status. Serum samples were drawn into ethylenediaminetetraacetic acid tubes, spun immediately at 3,000g at 4°C for 20 minutes, and frozen at −70°C for later analysis. External commercial testing on a subset of blood samples, as well as internal testing on control blood samples with known TNFR1 concentrations, confirmed the reliability and validity of the TNFR1 assays (correlation with external testing: r = 0.98).
The distributions of TNFR1 were determined. TNFR1 values were analyzed per standard-deviation increment. Since TNFR1 levels were not normally distributed, log transformation was also performed for consistency with prior analyses. Quartiles of TNFR1 were also analyzed as categorical variables, using the lowest quartile as the referent group.
Covariates
All analytical models included adjustment for the following variables, measured at baseline: age, sex, race/ethnicity, body mass index (weight in kilograms divided by the square of height in meters), hypercholesterolemia (defined by self-report, use of lipid-lowering therapy, or fasting total cholesterol level ≥240 mg/dL), diabetes mellitus (defined by self-report, fasting blood glucose level ≥126 mg/dL, or use of insulin/oral hypoglycemia medication), hypertension (defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg (based on the average of 2 blood pressure measurements) or patient self-report of a history of hypertension or use of antihypertension medication), smoking (defined as either nonsmoker or smoker within the past year), alcohol use (with moderate alcohol use classified as 1 drink/month-2 drinks/day), reported leisure-time physical activity (defined as any vs. none), social variables (marital status, health insurance status (classified as uninsured or Medicaid vs. Medicare or private insurance), number of friends (persons whom the participant knew well enough to visit in their homes), and duration of residence in the community (years)), and cognitive and mood factors (depression (defined as Hamilton Depression Scale score ≥12), performance on the Mini-Mental State Examination (analyzed as a continuous variable), and Spitzer Quality of Life Scale score) (24) .
Statistical analysis
The goal of this analysis was to determine whether levels of TNFR1 were associated with baseline BI ( Figure 1A ) and a steeper slope of decline over time ( Figure 1B ). We first calculated the distributions of TNFR1, baseline covariates, and BI, and we compared the distributions of variables based on availability of TNFR1 data to detect differences in the inflammatory laboratory cohort compared with the full NOMAS prospective study cohort. In order to assess possible selection bias in functional status related to availability of TNFR1 measurements, we compared the time trend of BI among cohort members with TNFR1 measurements with the time trend among cohort members without TNFR1 measurements using an interaction term for interaction between availability of TNFR1 measurements and time, in unadjusted and fully adjusted models.
Due to correlations among repeated measures of outcomes in the same individual, regression models using generalized estimating equations (GEE) with an identity link function were used to assess the association between TNFR1 levels and repeated measurements of BI, adjusting for baseline demographic variables (age, sex, and race/ethnicity), medical risk factors (body mass index, diabetes, hypertension, and hypercholesterolemia), lifestyle factors (smoking, alcohol use, and physical activity), social variables (marital status, insurance status, number of friends, and duration of residence in the community), and cognitive/mood factors (depressed mood, performance on the Mini-Mental State Examination, and Spitzer Quality of Life Scale score). In model-building, we sequentially added groups of variables in a prespecified manner. Specifically, the first model included no covariates, and successive models included demographic variables, vascular risk factors, social variables, and cognitive and mood factors.
In order to assess whether TNFR1 levels were associated with change in outcomes over time (slope, Figure 1B ), we included interaction terms for interaction between time of follow-up assessment and TNFR1. We also pursued an alternative modeling strategy using mixed models, and we added covariates in a similar manner as for the GEE analyses. We considered mixed-effect models as an alternative approach to GEE to assess the sensitivity of the analysis results. In principle, mixed-effect models will be more efficient than GEE under normality (with identity link). However, since GEE is robust against misspecification of the correlation structure, we considered the GEE analysis as our primary approach (25, 26) . We used the quasi-likelihood under the independence model criterion (QIC) for GEE models and Akaike's information criterion for mixed models as the model selection criteria after considering candidate final models. Various model diagnostic procedures, including tests of linearity, residual plots, and goodness-of-fit measures, were used to evaluate the final model. Spline regression was performed to evaluate lack of linearity in the association between TNFR1 levels and functional trajectories. There was no evidence to suggest lack of linearity in the final models. As a working correlation structure for the GEE models, we chose the exchangeable (intraclass) structure and compared the QIC obtained using this model with the QIC obtained using the unstructured working correlation structure. In order to assess whether interval vascular events such as clinical stroke and MI were implicated in the trajectory of functional status, we conducted a second set of analyses in which stroke and MI were included as time-varying covariates. We were interested in testing whether the relationship between TNFR1 and functional status remained even after adjusting for these events.
In a sensitivity analysis, we examined whether the relationship between TNFR1 levels and functional status differed for mobility domains of the BI (transfers, mobility, and stair use) and nonmobility domains (feeding, bathing, grooming, dressing, bowels, bladder, and toilet use). We analyzed these relationships separately in unadjusted and fully adjusted models. Table 1 shows distributions of variables in the cohort, stratified by availability of TNFR1 measurements (n = 1,863 with TNFR1). There were significant differences in the distributions of several variables based on availability of TNFR1 measurements, but there were no differences in major vascular risk factors. There were 21,466 BI assessments in total-a mean of 11.5 BI assessments (median, 13) per individual. There were no differences in the time trend of BI when the cohort with TNFR1 measurements was compared with the cohort without TNFR1 measurements, in unadjusted (P = 0.14) or fully adjusted (P = 0.6) models, affirming that there was no significant selection bias in functional status related to availability of TNFR1 measurements. The mean TNFR1 level was 2.57 mg/L, with a median of 2.28, an interquartile range of 1.67-2.89, and a standard deviation of 1.72. Log-transformed TNFR1 levels followed a normal distribution.
RESULTS
As shown in Table 2 , higher standardized TNFR1 levels were associated with lower baseline functional status as well as accelerated decline over time. In the fully adjusted model including adjustment for stroke and MI occurring during follow-up, each standard-deviation increase in TNFR1 level was associated with a mean decrease of 0.93 BI points (BI score change = −0.93, 95% confidence interval (CI): −1.59, −0.26) at baseline, as well as an additional 0.36 points per year of decline over time (BI score change = −0.36, 95% CI: −0.69, −0.03), over and above the 0.52 points per year of BI decline (BI score change = −0.52, 95% CI: −0.73, −0.31) in the entire cohort. There was a similar pattern when log TNFR1 levels were examined as the primary predictor; in the fully adjusted model, increasing levels of log TNFR1 were associated with a 0.63-point lower BI score at baseline (BI score change = −0.63, 95% CI: −1.07, −0.18) and a loss of 0.18 additional BI points per year (BI score change = −0.18, 95% CI: −0.35, −0.002).
When quartiles of TNFR1 were examined (Table 3) , higher quartiles of TNFR1 were associated with additional decline in function over time. In the fully adjusted model, the highest quartile of TNFR1 was associated with an additional 0.72 BI points of decline per year (BI score change = −0.72, 95% CI: −1.34, −0.10) compared with the lowest TNFR1 quartile. Similarly to the GEE models, in a fully adjusted mixed model, increasing TNFR1 levels were associated with a lower baseline BI score (BI score = −1.05, 95% CI: −1.40, −0.70) as well as accelerated decline in function over time (−0.43 additional BI points per year per unit increase in TNFR1 levels; 95% CI: −0.62, −0.23).
For the sensitivity analysis of BI domain, as well as 3 other sensitivity analyses (adding possible MI to the definition of MI, excluding persons with baseline coronary artery disease, and excluding persons with a baseline BI score less than 100 (n = 422)), model results did not differ significantly from those of the primary analyses and are not presented here.
DISCUSSION
We found that higher TNFR1 levels were associated with lower baseline functional status, as well as accelerated decline over time. NOMAS is a large, population-based study with frequent, regular measurements of functional status, and it is well-suited to the estimation of trajectories of functional status over time and identification of the key influencing factors. There was an overall decline in functional status over time in the entire cohort. Increasing levels of TNFR1, examined using different cutoffs and variable definitions, were associated not only with reduced baseline functional status but also with additional annual decline in function. For each standarddeviation increment in TNFR1 levels, baseline functional scores were lower, equivalent to the decline in function associated with 2 years of aging in this sample, and almost a doubling of the decline in functional status over time. Stated differently, TNFR1 levels in the highest quartile were associated with a greater-than-tripling of the slope of decline in functional status, to a total of 1 BI point per year-equivalent to the loss of 1 entire Activity of Daily Living level every 5 years. Importantly, these changes were independent of stroke and MI, since we adjusted for the occurrence of these events during follow-up. These changes were seen in both mobility and nonmobility domains of the BI, the implications of which will require further study.
One potential mechanism through which TNFR1 levels may account for decreased function and accelerated decline is subclinical vascular disease. Indeed, several prior studies have found associations between TNFR1 and vascular outcomes and mortality. In an early cross-sectional analysis carried out among 279 persons in NOMAS (27) , greater TNFR1 levels were associated with carotid atherosclerosis among those under 70 years of age. In a more recent longitudinal analysis in the NOMAS cohort (28), 1,862 participants were prospectively followed for a mean of 8.4 years for mortality and cause of death. Greater TNFR1 levels were associated with increased risk of all-cause and nonvascular mortality, and the magnitude of association was higher among persons with lower socioeconomic status. In a population-based study, the Oxford Vascular Study (29) , 15 biomarkers were tested in 929 patients with minor stroke and transient ischemic attack. Among the biomarkers tested, 4 were associated with all-cause death: TNFR1, von Willebrand factor, heart-type fatty-acid-binding protein, and N-terminal pro-B-type natriuretic peptide. Among 184 persons consecutively admitted to a hospital for MI, TNFR1 was independently associated with risk of heart failure or death over a median of 406 days of follow-up (30) . TNFR1 has also been shown to be a prognostic factor in cancer (31, 32) . Several studies have also examined associations between TNFR1 levels and neurological diseases and patient-centered outcomes. Among 72 persons with mild cognitive impairment followed for a mean of 18 months, higher serum TNFR1 levels were associated with increased risk of conversion to Alzheimer disease (33) . In a case-control study of 46 persons with Parkinson disease and 23 controls, those with Parkinson disease had higher TNFR1 levels (34) . Among 395 lung transplant candidates (35) , frailty, as assessed by the Fried Frailty Phenotype, was associated with higher TNFR1 levels in a case-control analysis. Using meta-analytical techniques among 6 cohorts, Peterson et al. (36) found higher TNFR1 levels to be associated with poorer physical performance after adjustment for age, body mass index, sex, and race. Finally, among 1,006 elderly community-dwelling participants (37), elevated TNFR1 levels were associated with incident inability to walk 400 m at 6-year follow-up, but repeated outcome assessments were not made as in the current analysis.
There are several possible mechanisms that could explain the association between TNFR1 and decreasing function seen in this study, which notably involved persons who were not selected by diagnosis of an inflammatory disorder, as in many prior studies. TNF is a cytokine that is implicated in various biological and pathological processes and is produced by multiple types of cells, including neuronal tissue, immune cells, vascular endothelial cells, adipocytes, cardiac myocytes, and fibroblasts (1). Studies in both animals (8) and humans (1) have demonstrated a role for TNF pathways in acute and long-term responses to cerebrovascular disease, frailty, and disability (9) . TNF pathways have acute and chronic inflammatory effects depending on the specific stimulating factor, duration of exposure, and milieu of activation (10) . In this study, we observed an association between increasing TNFR1 levels and decreasing function over time, suggesting that TNF activation may have chronic, ongoing detrimental effects on peripheral or central nervous system structure and function (11) . Furthermore, prior studies have shown associations between functional status and other inflammatory biomarkers, including C-reactive protein (38, 39) and interleukin 6 (40), suggesting that a common mechanism of inflammation may cause functional decline. We are currently engaged in analyses of other inflammatory biomarkers to test associations with functional trajectories, and further research would clarify these relationships.
Strengths of this analysis include a large, population-based cohort with repeated, regular measurements of functional status with a validated scale. Whereas prior studies have demonstrated associations between inflammatory biomarkers and outcomes at single time points, the current analysis measured both baseline functional status and the trajectory of change over time. The quality of data in this study was high, and there was no evidence of bias in the timing of follow-up assessments or loss to follow-up. There was also regular surveillance for vascular events and hospitalization and expert adjudication of events. Biomarkers were measured according to standard procedures, and we adjusted for confounding factors in the models. One limitation of the proposed study involves deficiencies in the primary measure. The BI is subject to ceiling effects and is insensitive to small changes in disability (41) . Analyzing BI scores as a continuous variable is advantageous, since this approach can capture and quantify the variance and course of change over time, which would likely not be captured by using a categorical or dichotomous variable (22, 23) . One advantage of the BI is that it is widely used in stroke research, which allows comparison with prior studies, and it is also not a stroke-specific scale, which allows its use in a stroke-free population.
There are several implications of our findings. The findings highlight the importance of measuring patient-centered outcomes, analyzing not only single time points but trajectories over time, and the use of epidemiologic and not only administrative (claims-based and event-based) data, due to the need to reliably measure outcomes. Using a study design involving these elements, we have identified a strong and consistent association between the inflammatory biomarker TNFR1 and long-term trajectories of functional status. Specific agents target the TNF pathway, such as etanercept, which binds the TNF receptor and has been proven to be effective for specific autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. To the extent that immune mechanisms play a role in other forms of age-related and vascular functional decline, modulation of immune function may also slow functional decline. Animal models, for example, provide evidence that inhibitors of the TNF pathway can reduce poststroke functional decline (8) . Further research is needed to clarify the mechanisms by which TNFR1 is associated with accelerated functional decline in humans and to clarify whether an intervention that targets the TNF pathway may modify this decline. 
